HARBOR 试验中接受按需雷珠单抗治疗的患者视网膜下液和/或视网膜内液复发的模式
该研究为 HARBOR 试验(NCT00891735)的事后分析,纳入基线存在视网膜下液和/或视网膜内液且液体消退≥3个月后复发的 222 只眼,比较基线液体位置与复发位置。复发时液体最常见于中心位置(69%),基线中心有液体者复发多在相同位置(72%,其他位置为 47%-53%),复发液体类型多与基线相同(视网膜下液 64%,视网膜内液 75%),37%(39/105)的眼在 new 位置复发,其中最常见为中心(53%)。
要点
- 基线时液体在各位置分布均匀,但复发时液体最常见于中心位置(69%)。
- 基线中心有液体者复发多在相同位置(72%,其他位置为 47%-53%)。
- 37%(39/105)的眼在 new 位置复发,其中最常见为中心(53%)。
核心结论
- 尽管基线时视网膜下液和/或视网膜内液位置分布均匀,但复发液体通常位于中心位置。
- 作者识别出液体复发位置与基线不同的亚组眼,可能提示 new 脉络膜新生血管。
研究设计与样本
- HARBOR 试验(NCT00891735)的事后分析,纳入基线存在视网膜下液和/或视网膜内液且液体消退≥3个月后复发的患者(N=222)。
主要发现
- 基线时液体在各位置分布均匀;复发时液体最常见于中心位置(69%)。
- 基线中心有液体者复发多在相同位置(72%,其他位置为 47%-53%)。
- 复发液体类型多与基线相同(视网膜下液 64%,视网膜内液 75%)。
- 37%(39/105)的眼在 new 位置复发,其中最常见为中心(53%)。
- 视网膜下液消退至复发期间,最佳矫正视力平均提高 2.2 个字母(95%CI 0.4-4.0)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate subretinal fluid (SRF) and/or intraretinal fluid recurrence in patients with neovascular age-related macular degeneration who received as-needed (PRN) ranibizumab in a HARBOR (NCT00891735) post hoc analysis. METHODS: Analyses included patients with SRF and/or intraretinal fluid at baseline and fluid recurrence after a ≥3-month absence (N = 222). Baseline fluid location(s) were compared with location of recurrence after a ≥3-month absence. RESULTS: At baseline, fluid was equally distributed across all locations. On recurrence, the location was most frequently central (69%). Eyes with central fluid at baseline typically had recurrence in the same location (72% vs. 47%-53% with fluid in other locations). The type of recurrent fluid was typically the same as at baseline (SRF, 64%; intraretinal fluid, 75%). Overall, 37% (39/105) of eyes exhibited fluid recurrence in a new location, most frequently central (53%). There was a significant gain in best-corrected visual acuity (mean [95% confidence interval], +2.2 [0.4-4.0] letters) between the months of SRF resolution and recurrence. CONCLUSION: Although the location of SRF and/or intraretinal fluid was equally distributed at baseline, recurrent fluid was typically centrally located. The authors identified a subgroup of eyes exhibiting fluid recurrence in a different location than at baseline, potentially indicating new choroidal neovascularization.
引用
- Adrean SD, Chaili S, Hill L, et al. PATTERNS OF SUBRETINAL AND/OR INTRARETINAL FLUID RECURRENCE IN PATIENTS WHO RECEIVED AS-NEEDED RANIBIZUMAB THERAPY IN THE HARBOR TRIAL. Retina. 2022. PMID: 36729084. doi:10.1097/IAE.0000000000003708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。